Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Covington
Fuji
Merck
Chinese Patent Office
Moodys
QuintilesIMS
Medtronic
UBS
Deloitte

Generated: October 21, 2017

DrugPatentWatch Database Preview

Guerbet Company Profile

« Back to Dashboard

What is the competitive landscape for GUERBET, and what generic and branded alternatives to GUERBET drugs are available?

GUERBET has four approved drugs.



Summary for Applicant: Guerbet

US Patents:0
Tradenames:5
Ingredients:4
NDAs:4
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Guerbet
OXILAN-350
ioxilan
INJECTABLE;INJECTION020316-002Dec 21, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Guerbet
OXILAN-300
ioxilan
INJECTABLE;INJECTION020316-001Dec 21, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Guerbet
DOTAREM
gadoterate meglumine
SOLUTION;INTRAVENOUS204781-002Mar 20, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Guerbet
DOTAREM
gadoterate meglumine
SOLUTION;INTRAVENOUS204781-002Mar 20, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Guerbet
HEXABRIX
ioxaglate meglumine; ioxaglate sodium
INJECTABLE;INJECTION018905-002Jul 26, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Guerbet
DOTAREM
gadoterate meglumine
SOLUTION;INTRAVENOUS204781-003Mar 20, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Guerbet
LIPIODOL
ethiodized oil
OIL;INTRALYMPHATIC, INTRAUTERINE009190-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Guerbet
DOTAREM
gadoterate meglumine
SOLUTION;INTRAVENOUS204781-003Mar 20, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Guerbet
DOTAREM
gadoterate meglumine
SOLUTION;INTRAVENOUS204781-001Mar 20, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Guerbet
DOTAREM
gadoterate meglumine
SOLUTION;INTRAVENOUS204781-004Mar 20, 2013RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Guerbet

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Guerbet
OXILAN-300
ioxilan
INJECTABLE;INJECTION020316-001Dec 21, 1995► Subscribe► Subscribe
Guerbet
HEXABRIX
ioxaglate meglumine; ioxaglate sodium
INJECTABLE;INJECTION018905-002Jul 26, 1985► Subscribe► Subscribe
Guerbet
HEXABRIX
ioxaglate meglumine; ioxaglate sodium
INJECTABLE;INJECTION018905-002Jul 26, 1985► Subscribe► Subscribe
Guerbet
HEXABRIX
ioxaglate meglumine; ioxaglate sodium
INJECTABLE;INJECTION018905-002Jul 26, 1985► Subscribe► Subscribe
Guerbet
OXILAN-350
ioxilan
INJECTABLE;INJECTION020316-002Dec 21, 1995► Subscribe► Subscribe
Guerbet
HEXABRIX
ioxaglate meglumine; ioxaglate sodium
INJECTABLE;INJECTION018905-002Jul 26, 1985► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
QuintilesIMS
Harvard Business School
Moodys
US Department of Justice
Merck
Colorcon
Baxter
Citi
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot